Drug intelligence / Profile preview

fentanyl + propofol

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

The combination of fentanyl and propofol is widely used for procedural sedation and anesthesia in various clinical settings, including outpatient procedures, endoscopy, cataract surgery, and minor surgical interventions. Fentanyl is a potent synthetic opioid analgesic that acts primarily as a mu-opioid receptor agonist to provide pain relief. Propofol is an intravenous anesthetic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor to induce hypnosis and sedation[6][5]. When used together, these drugs have synergistic effects—fentanyl enhances analgesia while allowing lower doses of propofol for effective sedation. This combination results in rapid onset of action, stable hemodynamic profiles with decreased heart rate and blood pressure, reduced drug requirements for both agents, minimal side effects, high patient satisfaction rates, and faster recovery times compared to either drug alone[4][5][8]. The combination is not marketed as a fixed-dose product but rather administered concomitantly by clinicians. Developed by AstraZeneca (propofol) and Janssen Pharmaceuticals/Johnson & Johnson (fentanyl).

Brand names
fentofol
Other names
propofol-fentanylfentanyl-propofolpropofol and fentanyl combination
02

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)GABRB2 (GABA-A receptor subunit beta-2)GABRB3 (GABA-A receptor subunit beta-3)

Beyond the preview

Go deeper on fentanyl + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + propofol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call